141 related articles for article (PubMed ID: 29725530)
1. Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.
Makino T; Otsuka H; Hata Y; Koezuka S; Azuma Y; Isobe K; Sugino K; Ebihara S; Homma S; Iyoda A
Mol Clin Oncol; 2018 May; 8(5):647-652. PubMed ID: 29725530
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease.
Azuma Y; Sano A; Sakai T; Koezuka S; Otsuka H; Tochigi N; Isobe K; Sakamoto S; Takai Y; Iyoda A
BMC Pulm Med; 2021 May; 21(1):174. PubMed ID: 34020622
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
4. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
5. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
6. Preoperative management using inhalation therapy for pulmonary complications in lung cancer patients with chronic obstructive pulmonary disease.
Takegahara K; Usuda J; Inoue T; Ibi T; Sato A
Gen Thorac Cardiovasc Surg; 2017 Jul; 65(7):388-391. PubMed ID: 28281043
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD.
Mizuno Y; Shirahashi K; Yamamoto H; Matsumoto M; Miyamoto Y; Komuro H; Hagiwara K; Doi K; Iwata H
Minerva Surg; 2021 Dec; 76(6):592-597. PubMed ID: 34047529
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease.
Yuasa M; Tanaka Y; Tanaka T; Kashiwada T; Taniuchi N; Saito Y; Seike M; Hino M; Gemma A
Cureus; 2021 Oct; 13(10):e19168. PubMed ID: 34873511
[TBL] [Abstract][Full Text] [Related]
9. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
10. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
11. Preoperative inhalation therapy for patients with chronic obstructive pulmonary disease undergoing lung surgery: a retrospective study.
Machino R; Shimoyama K; Nagayasu T; Tagawa T
J Cardiothorac Surg; 2022 Nov; 17(1):294. PubMed ID: 36434678
[TBL] [Abstract][Full Text] [Related]
12. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
[TBL] [Abstract][Full Text] [Related]
13. Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study.
Lee SY; Lee JS; Lee SW; Oh YM
J Thorac Dis; 2021 Jan; 13(1):169-177. PubMed ID: 33569197
[TBL] [Abstract][Full Text] [Related]
14. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
15. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
16. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404
[TBL] [Abstract][Full Text] [Related]
17. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
Oba Y; Chandran AV; Devasahayam JV
COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
[TBL] [Abstract][Full Text] [Related]
18. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis.
Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T
Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
